Researchers from Sanford Burnham Prebys and the University of California San Diego have unveiled a promising therapeutic strategy that could transform the treatment of high-grade serous ovarian cancer (HGSOC), one of the deadliest and most treatment-resistant forms of ovarian cancer. Published in Cell Reports, the study demonstrates that inhibiting focal adhesion kinase (FAK)—a protein overexpressed in HGSOC—can activate the immune system to recognize and attack tumors, potentially overcoming long-standing barriers to effective immunotherapy.
HGSOC is notoriously difficult to treat because it employs sophisticated mechanisms to suppress the body’s immune response, shielding cancer cells from attack. Even advanced immunotherapies designed to boost immune activity often fail in these tumors. The new research shows that targeting FAK can disrupt these defenses by altering the tumor microenvironment, allowing immune cells to infiltrate and mount a more effective attack.
FAK’s tumor-protective role stems from its overexpression in more than 75% of HGSOC cases, a factor strongly associated with poor patient survival. Preclinical studies suggest that combining FAK inhibitors with chemotherapy produces a synergistic effect, prompting ongoing Phase II clinical trials. However, until now, the specific immune mechanisms through which FAK supports tumor growth remained unclear.
Using a mouse model that mimics aggressive, chemotherapy-resistant HGSOC, researchers tested combinations of FAK inhibitors with chemotherapy and immunotherapy. The triple combination yielded striking results: tumor progression was significantly controlled, survival rates improved, and immune cell infiltration—including T and B lymphocytes—was enhanced within tumors.
A key discovery involved macrophages, immune cells traditionally seen as immunosuppressive in tumors. FAK inhibition reprogrammed these macrophages to actively coordinate anti-tumor immunity by secreting the chemokine CXCL13. This chemical signal recruits T and B cells into the tumor, where they organize into tertiary lymphoid structures—localized hubs that amplify immune responses against cancer cells.
The study also uncovered a metabolic dimension to this immune activation. FAK inhibition triggered the release of omega-3 fatty acids, which further promoted macrophage reprogramming, linking tumor metabolism directly to immune function. This metabolic-immune interface represents a novel avenue for therapeutic intervention in precision oncology.
The translational potential of this approach is substantial. By combining FAK inhibitors with chemotherapy and immune checkpoint blockade, previously “cold” tumors—those resistant to immune attack—can potentially be converted into “hot” tumors more susceptible to immune surveillance. For patients with metastatic HGSOC, this strategy offers hope for improved outcomes where treatment options are currently limited.
Kevin Tharp, PhD, co-lead author, emphasized the paradigm shift in understanding macrophages: “When reprogrammed, resident peritoneal macrophages become central architects of adaptive immunity, challenging the traditional view of tumor-associated macrophages as primarily pro-tumor agents.”
The study’s success highlights the power of interdisciplinary collaboration, integrating cancer metabolism, immunology, and clinical oncology. While further research is required to refine these therapies and validate them across diverse patient-derived models, the findings provide a strong foundation for imminent clinical trials aiming to leverage FAK inhibition to enhance immune surveillance in ovarian cancer.
Beyond ovarian cancer, the research underscores a broader principle: metabolic signaling within tumors can be harnessed to modulate immunity, opening new frontiers in the design of next-generation cancer therapies. The identification of omega-3 fatty acids as immune-activating mediators also suggests potential synergies with nutritional and metabolic interventions.
This study marks a critical advance in the fight against ovarian cancer, offering a tangible strategy to overcome treatment resistance and empower patients’ immune systems to achieve durable tumor control.
